Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Is fibromuscular dysplasia underdiagnosed? A comparison of the prevalence of FMD seen in CORAL trial participants versus a single institution population of renal donor candidates.

Authors:
Nicholas J Hendricks Alan H Matsumoto John F Angle Aparna Baheti Saher S Sabri Auh W Park James R Stone James T Patrie Lance Dworkin Christopher J Cooper Timothy P Murphy Donald E Cutlip

Vasc Med 2014 Oct 31;19(5):363-7. Epub 2014 Jul 31.

Beth Israel Deaconess Medical Center, Boston, MA, USA.

Renal artery fibromuscular dysplasia (FMD) may be underdiagnosed. We evaluated the prevalence of FMD in CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) renal artery stent trial participants, in which FMD was an exclusion criterion for inclusion. We also evaluated the prevalence of FMD in a relatively healthy population of patients undergoing computed tomographic angiographic (CTA) screening for renal donor evaluation. All renal donor CTAs performed at our institution from January 2003 through November 2011 were retrospectively reviewed for the presence of FMD along with patient sex and age. These results were compared to angiographic core lab (ACL) findings for the CORAL trial. The CORAL ACL database contained 997 patients (mean age 69.3 years; 50% female). Fifty-eight (5.8%) CORAL trial patients (mean age 71.8 years; 75.9% female) demonstrated incidental FMD. The renal donor cohort included 220 patients (mean age 40.5 years; 64.5% female). Five (2.3%) demonstrated FMD (mean age 48.6 years; all female). The odds of FMD in the CORAL cohort were 2.65 times that seen in the renal donor cohort (95% CI: 1.12, 7.57). In C: onclusion, the 5.8% prevalence of renal artery FMD in the CORAL trial population, the presence of which was biased against, suggests underdiagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1358863X14544715DOI Listing
October 2014

Publication Analysis

Top Keywords

renal donor
20
fmd coral
16
coral trial
16
patients age
12
renal artery
12
prevalence fmd
12
fmd
10
renal
9
evaluated prevalence
8
donor cohort
8
fibromuscular dysplasia
8
trial participants
8
coral
7
age
5
trial
5
donor
5
sex age
4
age 486
4
patient sex
4
486 years
4

Altmetric Statistics


Show full details
10 Total Shares
3 Facebook Pages
5 Tweets
1 Wikipedia Pages
9 Citations

Similar Publications

Discovered cancers at postmortem donor examination: A starting point for quality improvement of donor assessment.

Authors:
Ilaria Girolami Desley Neil Dorry Lidor Segev Lucrezia Furian Gianluigi Zaza Ugo Boggi Giovanni Gambaro Tullia De Feo Marilena Casartelli-Liviero Massimo Cardillo Letizia Lombardini Laura Zampicinini Antonietta D'Errico Albino Eccher

Transplant Rev (Orlando) 2021 Feb 20;35(2):100608. Epub 2021 Feb 20.

Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy. Electronic address:

Background: clinical and imaging investigations allow a detailed assessment of an organ donor, but a quota of cancer still elude detection. Complete autopsy of donors is even less frequently performed, due to economic issues and increasing availability of high-quality imaging. The aim of this study is to gather evidence from the literature on donor malignancy discovered at autopsy following organ donation and to discuss the utility and limitations of autopsy practice in the field of transplantation. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients.

Authors:
Benedetta C Sallustio Benjamin D Noll Rong Hu Daniel T Barratt Jonathan Tuke Janet K Coller Graeme R Russ Andrew A Somogyi

Br J Clin Pharmacol 2021 Mar 1. Epub 2021 Mar 1.

Discipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, 5000.

Aim: Long-term use of the immunosuppressant tacrolimus is limited by nephrotoxicity. Following renal transplantation, the risk of nephrotoxicity may be determined more by allograft than by blood tacrolimus concentrations, and thus may be affected by donor CYP3A5 and ABCB1 genetics. Little is known regarding factors that determine tacrolimus intra-renal exposure. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Characterization of follicular T helper cells and donor-specific T helper cells in renal transplant patients with de novo donor-specific HLA-antibodies.

Authors:
Julien Subburayalu Sebastian Dolff Shilei Xu Ming Sun Monika Lindemann Andreas Heinold Falko M Heinemann Jan Willem Cohen Tervaert Ute Eisenberger Johannes Korth Alexandra Brinkhoff Andreas Kribben Oliver Witzke Benjamin Wilde

Clin Immunol 2021 Feb 24:108698. Epub 2021 Feb 24.

Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen 45147, Germany. Electronic address:

T follicular helper (T) cells are a heterogeneous subset of immunocompetent T helper (T) cells capable of augmenting B cell responses in lymphoid tissues. In transplantation, exposure to allogeneic tissue activates T cells increasing the risk of the emergence of de novo donor-specific HLA-antibodies (dnDSA). These can cause antibody-mediated rejection (AMR) and allograft loss. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

"Living Donor Liver Transplant in patients with Hepatorenal syndrome without the use of Intra-operative Renal Replacement Therapy, a single center experience".

Authors:
Shweta A Singh Aaditya Anil Prabhudesai Rajkumar Subramaniyan Kaushal Madan Vivek Yadav Vijaykant Pandey Vaibhav Nasa Sumit Goyal Dibya Jyoti Das Rajgopal M Acharya Shaleen Agarwal Subhash Gupta

Clin Transplant 2021 Feb 26:e14271. Epub 2021 Feb 26.

Center for Liver & Biliary Sciences, Max Super Speciality Hospital, New Delhi, 110017.

Background: CRRT is often used to support the intra-operative course during liver transplantation ( LT) for patients with HRS. However, the use of intraoperative CRRT (IOCRRT) is not without its problems. Living donor liver transplantation (LDLT) is a planned operation, andis possible without IOCRRT as the recipient can be optimised. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Rationale and design of the Kidney Precision Medicine Project.

Authors:
Ian H de Boer Charles E Alpers Evren U Azeloglu Ulysses G J Balis Jonathan M Barasch Laura Barisoni Kristina N Blank Andrew S Bomback Keith Brown Pierre C Dagher Ashveena L Dighe Michael T Eadon Tarek M El-Achkar Joseph P Gaut Nir Hacohen Yongqun He Jeffrey B Hodgin Sanjay Jain John A Kellum Krzysztof Kiryluk Richard Knight Zoltan G Laszik Chrysta Lienczewski Laura H Mariani Robyn L McClelland Steven Menez Dennis G Moledina Sean D Mooney John F O'Toole Paul M Palevsky Chirag R Parikh Emilio D Poggio Sylvia E Rosas Matthew R Rosengart Minnie M Sarwal Jennifer A Schaub John R Sedor Kumar Sharma Becky Steck Robert D Toto Olga G Troyanskaya Katherine R Tuttle Miguel A Vazquez Sushrut S Waikar Kayleen Williams Francis Perry Wilson Kun Zhang Ravi Iyengar Matthias Kretzler Jonathan Himmelfarb

Kidney Int 2021 Mar;99(3):498-510

Department of Medicine, University of Washington, Seattle, Washington, USA.

Chronic kidney disease (CKD) and acute kidney injury (AKI) are common, heterogeneous, and morbid diseases. Mechanistic characterization of CKD and AKI in patients may facilitate a precision-medicine approach to prevention, diagnosis, and treatment. The Kidney Precision Medicine Project aims to ethically and safely obtain kidney biopsies from participants with CKD or AKI, create a reference kidney atlas, and characterize disease subgroups to stratify patients based on molecular features of disease, clinical characteristics, and associated outcomes. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap